
Multiple Promising Compounds in Development for Rare Neurometabolic Disorders: NKH, UCD and X-ALD
Our Pipeline for Rare Neurometabolic Disorders
CLINICAL CANDIDATE
INDICATION​
PRECLINICAL
PHASE 1
PHASE 2
​​
Basket Trial
(NKH, UCD, Other Rare Metabolic Disorders*​​)
​​
​​
​Glycine Encephalopathy
(Potential Single Pivotal Trial Under NKH)
​
​​​
​​Urea Cycle Disorder​
(Potential Single Pivotal Trial under UCD)
​​​
LBX-100
LBX-200
​​
Glycine Encephalopathy
​
​​
Urea Cycle Disorder​​
​
LBX-400
​​
Urea Cycle Disorder​
​
LBX-300
​​​
Glycine Encephalopathy
​
​
​​Urea Cycle Disorder​​
​
505(b)(1) New Chemical Entity - Combination Therapies
505(b)(1) New Chemical Entity - Monotherapies
LEAD CANDIDATE
LEAD CANDIDATE
LEAD CANDIDATE
* Includes X-linked adrenoleukodystrophy (X-ALD), metachromatic leukodystrophy (MLD), leukoencephalopathy, van der Knaap syndrome, and X-linked cobalamine disorder.
Our Team
Our Executive Leadership
Our Board of Directors

Mstone Healthcare Partners
Liberyx’s controlling shareholder is Mstone Healthcare Partners, an entrepreneurial incubator building aesthetics and healthcare, life sciences, and AI-related companies. Mstone founds, staffs, develops, and grows portfolio companies by building upon novel technology as well as human and investment capital.